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Abstract
Patients affected by muscular dystrophies often show CNS abnormalities. 
Patients with dystrophinopathies exhibit intellectual disabilities and mental 
retardation, while subjects with facioscapulohumeral muscular dystrophy (FSHD) 
often show epilepsy. Dystrophin and associated proteins have important roles in 
the CNS. Many patients with Duchenne and Becker muscular dystrophies (DMD/
BMD) have cognitive impairment, learning disability, and variable degrees of 
mental retardation in addition to progressive muscular weakness. Unfortunately, 
the assessment of cortical function with TMS in DMD patients has not been able to 
delineate a clear picture and has yielded contradictory results. No TMS studies have 
been performed on BMD patients. Repetitive transcranial magnetic stimulation 
(rTMS) modulates cortical excitability, possibly by inducing a short-term increase 
in synaptic efficacy, and can be used to investigate motor cortex excitability in BMD 
patients. Changes in the size and threshold of motor evoked potentials (MEPs) and 
cortical silent period (CSP) duration evoked by rTMS delivered in 5 Hz trains of 
stimuli at suprathreshold intensity can be tested. Impaired muscular function might 
be partially compensated by an enhancement of motor excitability at the cortical 
level and/or at α-motoneuron level. TMS may thus offer a reliable means to char-
acterize also important neurophysiologic and pathophysiologic aspects of cortical 
involvement in muscular dystrophy.
Keywords: transcranial magnetic stimulation, paired-pulse TMS,  
motor cortical excitability, myopathy, muscular dystrophy
1. Introduction
Muscular dystrophy (MD) is characterized by an absence or disruption of 
dystrophin and associated proteins with a severe pathology of the skeletal muscu-
lature with severe motor disabilities and even premature death of the individual. 
These proteins do not only have an important function within the skeletal mus-
culature but also within the central nervous system. Thus, patients with muscular 
dystrophies often suffer from cognitive impairment, learning disability, and vari-
able degrees of mental retardation in addition to progressive muscular weakness 
[1–3]. Patients with facioscapulohumeral muscular dystrophy (FSHD) are often 
affected by epilepsy [4, 5]. However, the pathogenetic role played by the absence 
or disruption of dystrophin on CNS function has not been clarified so far.  
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Transcranial magnetic stimulation (TMS) is a proper method to assess brain 
cortical excitability that is disturbed in muscular dystrophies. A TMS assessment 
of brain cortical function in DMD patients has yielded contradictory results [6]. 
While Yayla et al. reported no CNS abnormalities and similar motor threshold 
(MT) values in DMD patients and healthy controls, Di Lazzaro et al. reported a 
higher MT for magnetic than for electrical stimulation in four DMD patients [7]. 
Methodological reasons, as well as the small sample size of the latter study, may 
account for the discrepancies. Because repetitive TMS (rTMS) modulates cortical 
excitability, possibly by inducing a short-term increase in synaptic efficacy [8], 
rTMS can be used to investigate motor cortex excitability in humans. Changes 
in the size and threshold of motor evoked potentials (MEPs) and cortical silent 
period (CSP) duration evoked by rTMS delivered in 5 Hz trains of stimuli at supra-
threshold intensity have been tested by Golaszewski et al. [9]. The main finding of 
this study was that 5 Hz-rTMS delivered in trains failed to elicit the normal MEP 
facilitation over the train in a group of Becker Muscular Dystrophy (BMD) patients 
with mental retardation or borderline mental retardation and BMD patients 
with normal intelligence and healthy controls did not show any abnormalities in 
5 Hz-rTMS MEPs and CSPs. The lack of MEP facilitation in mentally retarded or 
borderline BMD patients during the 5 Hz-rTMS train of stimuli may thus reflect an 
altered short-term synaptic enhancement.
With the means of transcranial magnetic stimulation, important neurophysi-
ologic and pathophysiologic aspects of cortical involvement in myopathies can be 
detected [10, 11]. So far, a few studies applying TMS have detected abnormalities in 
cortical reactivity and plasticity in MD patients.
2. Electrophysiological markers in muscular dystrophy
2.1 Motor threshold
In a study of Di Lazzaro et al. in a small group of DMD patients and a control 
group (n = 4), the threshold for evoking MEPs using electrical anodal stimulation 
was the same. Otherwise, the resting motor threshold (RMT) for a stimulation with 
a circular magnetic coil at the vertex was higher in the DMD patients [7]. The higher 
threshold was interpreted as a reduced cortical excitability that may be related to 
an abnormal synaptic function due to the deficiency of brain synaptic dystrophin. 
However, in a study about the cortical excitability in Duchenne muscular dystrophy 
investigating central motor conduction time (CMCT), cortical silent periods, and 
paired-pulse TMS, there were no statistical differences between a group of DMD 
children and a group of age-matched control children except lower MEP ampli-
tudes in the DMD children. Compared with a control group of healthy adults, the 
two children groups showed less short interval intracortical inhibition (SICI) and 
shorter CSP durations [6]. The difference between the two studies can be explained 
by the applied different methods, since in the study by Di Lazzaro et al., a circular 
coil was used and an unusual minimum stimulus intensity that evoked an EMG 
response of at least 100 μV in 100% of 20 consecutive trials was the accepted resting 
motor threshold. Besides the small sample size in the study of Di Lazzaro et al. can 
be an explanation for the difference.
Oliveri et al. found that in patients with myotonic dystrophy, the stimulus 
threshold intensity did not differ between patients and healthy controls, but the 
mean cortical motor latency and CMCT were significantly prolonged in the patients 
compared to the controls. This can be interpreted as a central motor delay and a 
decreased excitability of motor neurons in the myotonic dystrophy patients [12].
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In another study Di Lazzaro et al. [13] found that RMT was slightly increased in 
patients with FSHD as well as in patients with other muscle diseases such as limb-
girdle muscle dystrophy (LGMD) and polymyositis [13]. However, Liepert et al. 
[14] could not show a significant difference in RMT between a group of patients 
with different myopathies (including FSHD, LGMD, emerinopathy, adhalinopathy, 
multicore disease) and a group of control subjects [14].
2.2 Central motor conduction time
As mentioned above Oliveri et al. investigated MEPs elicited by cortical and 
cervical magnetic stimulation in 10 patients with myotonic dystrophy. While MEP 
cervical latency, absolute or relative amplitude, and RMT did not differ significantly 
between patients and controls, the mean cortical motor latency and CMCT were 
significantly prolonged in the patients compared with 10 healthy controls [12]. This 
central motor delay can be explained by a decreased motoneuron excitability.
In several further studies, it was found that CMCT was normal in patients with 
FSHD and LGMD [13, 14] as well as in patients with DMD [6, 7].
2.3 MEP amplitudes/areas
Yayla et al. further described in his study [6] with DMD patients that mean MEP 
response amplitudes and areas, as well MEP/compound muscle action potential 
(CMAP) amplitude ratios, had a tendency to be lower than those of a control group, 
but only the differences in MEP area values reached a statistical significance [6]. An 
explanation for the reduced amplitude of CMAPs and MEPs could be the muscle 
damage in the DMD patients. Otherwise, DMD patients showed an increased ratio 
of the F-wave and the compound motor action potential (F/CMAP ratio), indicative 
for an increased α-motoneuron excitability. The mean F-wave amplitudes were not 
significantly different between DMD patients and controls. Therefore, the reason 
for a higher F/CMAP ratio in the DMD group is difficult to explain. One explana-
tion may be an increased F-wave amplitude in the DMD patients that did not reach 
statistical significance especially due to their large variability. Another explanation 
may be the aforementioned low-amplitude CMAPs in DMD patients or an increased 
motor cortical excitability due to less SICI and shorter CSP durations in DMD 
patients with regard to healthy adult controls.
In the study of Liepert et al., MEP amplitudes of the first dorsal interosseous 
(FDI) and the deltoid muscle (DM) were increased in patients with different myopa-
thies compared to controls [14]. The recruitment of a larger group of corticospinal 
neurons by the TMS pulses due to an increased motor cortical excitability with a 
consecutive increased activation of the α-motoneuron pool may explain this finding.
Finally, in the study of Oliveri et al., the first MEP study in patients with myo-
tonic dystrophy, the mean MEP amplitudes did not differ between patients and 
controls [12].
2.4 Intracortical inhibition
In the study of Liepert et al. in myopathy patients with well-defined myopathies, 
the patients showed a reduction of SICI compared to an age-matched healthy 
control group [14]. This reduction of SICI was present in both clinically unaffected 
and affected muscles. In the patients, both MEP amplitudes and α-motoneuron 
excitability were enhanced, and, thus, it was concluded that excitability in myopa-
thy patients was enhanced at cortical and subcortical levels in order to compensate 
for the muscle weakness or because of use-dependent plasticity. In all patients 
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irrespective of the type of myopathy, a reduced intracortical inhibition was found. 
Obviously, this neurobiological mechanism of increased motor cortical excitability 
for compensation of muscle weakness is independent of a particular muscle pathol-
ogy in myopathies. However, with regard to the available electrophysiological data, 
there is no sufficient evidence to conclude that cortical disinhibition is a common 
feature of myopathies.
In 2004 Di Lazzaro et al. reported significantly reduced SICI in early-onset 
FSHD patients compared with patients suffering from other muscle diseases 
(LGMD and polymyositis) and healthy controls. Between polymyositis patients and 
controls, there was no significant difference in SICI [13].
2.5 TMS and fatigue
During fatiguing muscle exercise, a paired-pulse TMS paradigm can be applied 
to investigate the central inhibitory and excitatory mechanisms that occur at the 
motor cortical level. Paired-pulse TMS was already done in patients with multiple 
sclerosis and in healthy subjects [15, 16]. In a study of Schwenkreis et al., SICI 
has been applied prior to a fatiguing motor task, immediately post-exercise, and 
40 minutes post-exercise in MD patients and patients suffering from fibromyalgia 
syndrome (FMS) [17]. In the MD and FMS patients, SICI was already reduced 
pre-exercise. Healthy subjects did not show any pre-exercise SICI decrease but 
a significant SICI decrease post-exercise. Thus, reduced SICI may be a central 
compensatory mechanism for peripheral or central fatigue. MD patients may use 
this neurobiological mechanism of reduced SICI already under baseline conditions, 
probably due to permanent muscle weakness. Probably due to a ceiling effect, the 
MD and FMS patients may not be able to further decrease cortical inhibition during 
the fatiguing exercise. This may be an additional central mechanism to the fatigue 
in MD and FMS patients. A fatigue syndrome belongs to the typical clinical feature 
of these patients.
An altered peripheral nerve excitability and reduced SICI at baseline in patients 
with MD type 1 (DM1) with impaired myoelectric properties (mean power fre-
quency, muscle fiber conduction velocity) have been demonstrated in a study of 
Boerio et al. [18]. The remaining excitability parameters did not vary post-exercise 
in patients in contrast to the healthy controls.
In patients with colchicine myopathy with reported fatigue but no significant 
muscle weakness, Lin et al. investigated central compensatory mechanisms [19]. 
The patient and control group did not differ in the results. Obviously, there is no 
change in motor cortical excitability in acquired myopathy due to colchicine, while 
central reorganization may occur in patients with hereditary myopathy to compen-
sate for muscle weakness.
2.6 Cortical plasticity
Repetitive TMS has also been applied to investigate motor cortex plasticity 
in patients with Becker muscular dystrophy [9]. The rTMS-induced facilitation 
of MEPs was significantly reduced in mentally retarded or borderline mentally 
retarded classified BMD patients when compared with BMD patients with normal 
intelligence and age-matched healthy controls (see Figure 1a). The increase in the 
duration of the cortical silent periods was similar in both patient groups and con-
trols (see Figure 1b). These findings suggest an altered cortical short-term synaptic 
plasticity in glutamate-dependent excitatory circuits within the motor cortex in 
BMD patients with intellectual disabilities.
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Figure 1. 
(a and b) Changes in the size of motor evoked potentials (a) and in the duration of cortical silent period  
(b) in the FDI muscle during repetitive transcranial magnetic stimulation trains of 10 pulses delivered at 5 Hz 
in the 6 patients with Becker muscular dystrophy and mental retardation or borderline (BMD-Cog−), the 7 
patients with BMD and normal intelligence (BMD-Cog+), and the 10 age-matched healthy subjects (controls). 
Data are expressed as mean ± SE. Asterisks indicate significant differences (p < 0.05, Bonferroni adjusted) 




The studies reviewed here show that most TMS measurements vary considerably 
from study to study. The cause of this variability remains unclear, but the meth-
odological problem of TMS and technical factors, including the relatively small 
sample size in most studies or the difficulty of many patients (especially children) 
to achieve complete muscle relaxation, can explain this variability. Several TMS 
studies have provided electrophysiological evidence for abnormal motor cortical 
excitability and/or plasticity in patients with different myopathies. Applications of 
TMS to characterize musculoskeletal pathophysiology in patients with myopathies 
appear to be safe and can be developed in valuable biomarkers.
In a first study of patients with MD, TMS has been reported to have subclinical 
central motor conduction abnormalities suggesting that the integrity of the cortico-
spinal tract is also affected. This deficiency was considered one of the multisystem 
manifestations of muscle disease, regardless of muscle pathology [12]. However, 
these preliminary results were not confirmed by successive studies in other 
myopathies.
The reviewed TMS studies showed that it is possible to detect changes in motor 
cortex excitability in myopathy patients. The most important finding is a significant 
reduction in SICI compared to healthy controls.
In adult patients with various types of myopathies, including FSHD and 
LGMD, the mechanisms of intracortical inhibition are reduced. This finding 
has been interpreted as a compensatory mechanism within the central nervous 
system that helps patients with myopathy to regain muscle power. SICI deficiency 
in FSHD may be explained by overexpression of the gene encoding the diazepam 
binding inhibitor (DBI), which is expected to attenuate the effects of GABA on 
GABAA receptors by acting on the benzodiazepine binding site [20]. Thus, DBI 
can determine a reduction in SICI, a phenomenon that depends largely on intra-
cortical GABAA inhibitory mechanisms. It is interesting to note that a decrease in 
initial intracortical inhibition may prevent the subsequent use of this compensa-
tory mechanism within the central nervous system in fatiguing muscle exercises as 
can be seen in healthy subjects [17]. Reduced baseline SICI in MD can be con-
sidered compensatory because of peripheral weakness, whereas in fibromyalgia 
syndrome, reduced SICI should rather be considered as an indicator of primary 
central disinhibition. Also in DM1 patients, TMS revealed abnormalities in cortical 
excitability, thus suggesting the occurrence of intracortical dysfunction [18]. 
These results are consistent with the autopsy and neuroimaging studies showing 
that dysfunction of the brain can be accompanied by structural changes. As a 
result, a disturbance of neuronal architecture was detected in the autopsy of the 
brain [21]. In addition, a three-dimensional magnetic resonance imaging- 
controlled study demonstrated cerebral parenchymatrophy and hyperintensive 
lesions of the white matter [22], and PET scans showed a hypoperfusion in the 
prefrontal, temporal, and parieto-occipital lobes as well as in the basal ganglia, 
supporting the hypothesis of brain dysfunction in patients with DM1 [23].
In DM1 patients reduced intracortical facilitatory mechanisms (ICF) were found 
too [18]. Further, CNS excitability properties were markedly altered at the baseline 
and were not prone to be further impaired after a fatiguing exercise. Adjusting the 
cortical and neuromuscular features to the initial change may prevent increased 
fatigue after exercise performed with a maximum voluntary contraction percent-
age. The authors hypothesized that fatigue in MD patients may be mainly due to 
peripheral factors related to muscle pathology. Thus, MD patients were probably 
unable to reach the required force level of 50% of their maximal grip force for 
enough time to determine a reduction of corticospinal excitability, a marker of 
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central fatigue [24]. This may explain the lack of reduced MEP amplitudes after 
fatiguing exercise in these patients.
It is interesting to note that central compensatory mechanisms can be observed 
in patients with hereditary myopathies, whereas a single study on TMS in an 
acquired colchicine myopathies showed normal corticospinal excitability.
Many patients with dystrophinopathies (DMD and BMD) also suffer from cog-
nitive impairment, learning difficulties, and variable mental retardation in addition 
to progressive muscle weakness [1–3]. The role played by the absence or disruption 
of dystrophin within the central nervous system is unclear, and the pathogenic 
conditions leading to mental retardation in MD patients are still unknown. TMS 
investigation of cortical function in DMD patients did not delineate a clear picture 
of motor cortical abnormalities and led even to contradictory results. Yayla et al. 
did not report any motor cortical abnormalities [6], and Di Lazzaro et al. reported 
higher MT for magnetic than for electrical stimulation in four DMD patients [7]. As 
already discussed, methodological reasons, as well as the small sample size of the 
latter study, may account for these discrepancies.
During 5 Hz-rTMS in BMD patients, MEP facilitation as observed in healthy 
subjects was reduced in contrast to the above-reported study of Yayla et al. [6, 9]. 
5 Hz-rTMS MEP facilitation reflects mechanisms of short-term plasticity within 
the motor cortex that probably differ from those involved in the paired-pulse 
TMS facilitation and are likely related to an enhancement in the activity of I-wave 
generating circuits [25]. Intracortical facilitation in paired-pulse TMS is a complex 
phenomenon reflecting the activity of still poorly defined cortical circuits indepen-
dent from those involved in I-wave generation [26].
The results of the study of Golaszewski et al. indicate impaired cortical plastic-
ity in glutamate-dependent excitation circuits in mentally retarded BMD patients 
consistent with the results of several experimental studies indicating abnormal 
glutamatergic transmission in muscle diseases caused by mutations within the 
dystrophin-encoding gene [9]. In particular, the product of the dystrophin gene, 
dystrophin-71, in glutamate receptor signaling and possibly clustering, appears to 
be involved [27]. Besides, dystrophin-deficient mdx mice are more resistant to kai-
nic acid-induced seizures but not to GABA antagonist-induced seizures compared 
with control mice. In the mdx mice, the kainic acid receptor density in the brain 
was found to be significantly lower than in the control mice, although the density of 
muscarinic cholinergic receptors, another important neurotransmitter receptor for 
cognitive function, was normal. The disruption of the dystrophin complex may lead 
to an instability of kainate-type glutamate receptors on the synaptic membranes 
with resulting inefficient neurotransmission in DMD patients [28].
It is important to note that the rTMS approach cannot be used to study cortical 
plasticity in children with DMD because the safety guidelines for the TMS applica-
tion have been updated in the research and clinical environments [29]. The updated 
guidelines recommend that children should not be used as subjects for rTMS with-
out compelling clinical reasons. Alternatively, the paired associative stimulation 
(PAS) technique can be applied in MD children that provide information about dif-
ferent aspects of cortical plasticity. So far, PAS has not yet been applied in myopathy 
patients and MD children [30]. No study has measured cortical responsiveness or 
plasticity outside the motor cortex.
Integrated approaches using TMS in conjunction with high-density EEG may 
reveal altered cortical plasticity and functional connectivity across different neuro-
nal networks, similar to several other neurological and psychiatric disorders.
TMS can also affect brain function during repeated administration. rTMS can 
modulate cortical excitability and induce long-lasting neuroplastic changes [31, 32]. 
rTMS has been used for therapeutic purposes in patients with many neurological 
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and psychiatric disorders because it can induce long-term modulation of brain 
activity in the target brain region and across brain networks via transcranial 
induction of electrical currents in the brain. rTMS involves mechanisms of synaptic 
plasticity, and, recently, an association between rTMS-induced aftereffects and the 
induction of synaptic plasticity has been demonstrated [33]. Since abnormal corti-
cal excitability and neuroplastic changes may play a role in the clinical expression 
of myopathies (including muscle weakness and fatigue), their modulation by rTMS 
may have a therapeutic potential. If the abovementioned changes affect motor 
control, treatment, or rehabilitation, strategies based on these abnormalities can 
help to improve the outcome of myopathy patients in neurorehabilitation.
In summary, only a few studies have used TMS for the electrophysiological 
characterization of cortical involvement in neuromuscular diseases. However, 
TMS may be promising as an electrophysiological biomarker in patients with 
muscular dystrophy and other myopathies, in identifying potential therapeutic 
targets and in monitoring the effects of suspected pharmacological applications. 
Neuromodulation by rTMS may have a therapeutic potential in the future to induce 
synaptic plasticity as a compensatory neurobiological mechanism for progressive 
muscle weakness to improve treatment outcome.
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